Our study confirms the FLT3–ITD AR level as an independent prognostic factor for CR, OS (cutoff 0.5), and RFS (cutoff 0.8) in this cohort of fit patients with AML in the pre-FLT3 inhibitor era. The gene discussed is FLT3; the disease is acute myeloid leukemia.